Suzetrigine

Contraindicated

Suzetrigine Ketoconazole Topical Extina® Foam Increased suzetrigine and M6-SUZ (active metabolite) exposure and an increased risk of suzetrigine-related adverse reactions Details

Major

Suzetrigine Clindamycin ANTIROBE Explained Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Suzetrigine Colchicine Colcrys Explained Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Suzetrigine Simvastatin Flolipid Explained Reduced sensitive CYP3A substrate exposure and reduced efficacy of sensitive CYP3A substrate Details Suzetrigine Abemaciclib Verzenio Explained Reduced sensitive CYP3A substrate with NTI exposure and reduced efficacy of sensitive CYP3A substrate with NTI Details Suzetrigine Acalabrutinib Calquence Reduced sensitive CYP3A substrate with NTI exposure and reduced efficacy of sensitive CYP3A substrate with NTI Details Suzetrigine Atogepant Qulipta Reduced sensitive CYP3A substrate exposure and reduced efficacy of sensitive CYP3A substrate Details Suzetrigine Avapritinib Ayvakit Reduced sensitive CYP3A substrate exposure and reduced efficacy of sensitive CYP3A substrate Details Suzetrigine Amlodipine Amvaz® Reduced amLODIPine exposure Details Suzetrigine Avanafil Stendra Reduced sensitive CYP3A substrate exposure and reduced efficacy of sensitive CYP3A substrate Details Suzetrigine Axitinib Inlyta Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Suzetrigine Bosutinib Bosulif Reduced sensitive CYP3A substrate with NTI exposure and reduced efficacy of sensitive CYP3A substrate with NTI Details Suzetrigine Brigatinib Alunbrig Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Suzetrigine Budesonide Entocort Reduced sensitive CYP3A substrate exposure and reduced efficacy of sensitive CYP3A substrate Details Suzetrigine Budesonide Nasal Spray Rhinocort Reduced sensitive CYP3A substrate exposure and reduced efficacy of sensitive CYP3A substrate Details Suzetrigine Budesonide Oral Inhalation Pulmicort Reduced sensitive CYP3A substrate exposure and reduced efficacy of sensitive CYP3A substrate Details Suzetrigine Clindamycin Injection ANTIROBE Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Suzetrigine Clindamycin Topical C/T/S® Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Suzetrigine Clindamycin Vaginal Cleocin Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Suzetrigine Cobimetinib Cotellic Reduced sensitive CYP3A substrate with NTI exposure and reduced efficacy of sensitive CYP3A substrate with NTI Details Suzetrigine Cyclosporine Injection Atopica Reduced sensitive CYP3A substrate with NTI exposure and reduced efficacy of sensitive CYP3A substrate with NTI Details Suzetrigine Cyclosporine Ophthalmic Cequa Reduced sensitive CYP3A substrate with NTI exposure and reduced efficacy of sensitive CYP3A substrate with NTI Details Suzetrigine Dasatinib Phyrago Reduced sensitive CYP3A substrate with NTI exposure and reduced efficacy of sensitive CYP3A substrate with NTI Details Suzetrigine Dihydroergotamine Injection DHE-45® Injection Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Suzetrigine Dihydroergotamine Nasal Spray Migranal Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Suzetrigine Docetaxel Beizray Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Suzetrigine Docetaxel Injection Beizray Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Suzetrigine Dofetilide Tikosyn Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Suzetrigine Elacestrant Orserdu Reduced sensitive CYP3A substrate exposure and reduced efficacy of sensitive CYP3A substrate Details Suzetrigine Entrectinib Rozlytrek Reduced sensitive CYP3A substrate with NTI exposure and reduced efficacy of sensitive CYP3A substrate with NTI Details Suzetrigine Everolimus Afinitor Reduced sensitive CYP3A substrate with NTI exposure and reduced efficacy of sensitive CYP3A substrate with NTI Details Suzetrigine Felodipine Plendil® Reduced sensitive CYP3A substrate exposure and reduced efficacy of sensitive CYP3A substrate Details Suzetrigine Fentanyl Transdermal Patch Duragesic® Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Suzetrigine Finerenone Kerendia Reduced sensitive CYP3A substrate exposure and reduced efficacy of sensitive CYP3A substrate Details Suzetrigine Ibrexafungerp Brexafemme Reduced sensitive CYP3A substrate exposure and reduced efficacy of sensitive CYP3A substrate Details Suzetrigine Ibrutinib Imbruvica Reduced sensitive CYP3A substrate exposure and reduced efficacy of sensitive CYP3A substrate Details Suzetrigine Infigratinib Truseltiq Reduced sensitive CYP3A substrate exposure and reduced efficacy of sensitive CYP3A substrate Details Suzetrigine Ivabradine Corlanor Reduced sensitive CYP3A substrate exposure and reduced efficacy of sensitive CYP3A substrate Details Suzetrigine Lefamulin Xenleta Increased suzetrigine and M6-SUZ (active metabolite) exposure and an increased risk of suzetrigine-related adverse reactions Details Suzetrigine Lenacapavir Injection Sunlenca Increased suzetrigine and M6-SUZ (active metabolite) exposure and an increased risk of suzetrigine-related adverse reactions Details